Exchange: NASDAQ·Updated 07:31 PM EST
SNDX logo

SNDX Syndax Pharmaceuticals Inc

$8.73
$0.41
(4.49%)
Today
Closed $8.72
$0.01
(0.12%)
After Hours
Reported EarningsNov 2
Mkt Cap$785.05M
Vol2.18M

About SNDX

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.
42

Bearish Sentiment

How do you feel about SNDX?

dgbio
$SNDX Steve Closter, CCO, on the call: "ASH is going to be great. There is so much good data coming".
2
8
dgbio
$SNDX "...approximately 40% of R/R NPM1m patients proceed to HSCT after receiving Revuforj, of which about 50% have resumed therapy post-transplant". This is much higher than expected, almost on the level of KMT2A. It was just 11% in the pivotal trial. 40%!!! Just wow!
11
BiotechSwings
nobody brings 19 abstracts to ASH by accident imo $SNDX, Dec 12 to 15 in New Orleans 14 revumenib abstracts, 7 oral, plus 5 axatilimab with long term AGAVE 201 data behind them BEAT AML final Dec 13, SAVE Dec 14, investor event that same morning closed 9.59 today, up 1.1%, just off the 9.15 low it tagged Monday Q3 revenue did 83.3 million, up 82% vs last year, and the stock is still sitting down here into its biggest data slate of the year
10
dgbio
$SNDX Let's assume blexi is better in R/R as a monotherapy. Now, how much sales Syndax derives from the R/R mono? We have the numbers to estimate that from the latest call. At least 40% in combo treatments and we know combo treatments have at least 2x better response and at least 2x better duration of the response. And at least 20% are going to have maintenance treatment which is also at least 2x longer than R/R mono. Simple math gives us an estimate that only about 25% of the current sales are to patients on primary (non-maintenace) monotherapy. In a year, with combo regimens improving, maintenance treatments growing and pre-emptive strategies emerging this number is going to be even lower. So when JNJ gets to the market, how many patients are going to be there looking for the R/R mono treatment? Probably, only some frail patients not eligible for combos. Would that impact Syndax's top-line? Very little.
10
Georgeson
$SNDX For what it is worth: Syndax Pharmaceuticals (SNDX) Analyst Updates Analysts are split between aggressively defending the stock as an oversold buying opportunity and adjusting price targets down to reflect immediate pipeline execution risks. • H.C. Wainwright: Trimmed its price target slightly from $38.00 to $36.00 but emphatically reiterated a Buy rating. The firm noted that the severe market overreaction presents an attractive long-term buying opportunity, as the core commercial trajectory for Revuforj in AML remains intact. • Citigroup: Strongly reiterated its Street-high $57.00 price target and Buy rating. Citi called the plunge an "attractive entry point," reminding investors that non-core pipeline setbacks (like the recent IPF clinical miss) were never included in their financial models. They also highlighted Niktimvo's surging margin performance (reaching 34% in as a clear path toward company-wide profitability. •
9
Hawksssss
$SNDX Yeah, maybe I'll make a few comments. So for us, I mean, pointed out probably most specifically with the BD-AML trial, which has been updated for this year's ASH. where the profile looks almost unbeatable, right? I mean, in terms of CR rate, we're close to 70% CR rate, not CRCRH, or but CR rate, so that's double what you would see with Vyala-A, what you did see with Vyala-A. And when you look at overall survival out over 2 years, right, versus what you would see with Vyala-A at about 14, 15 months. So we are— again, this is an updated data set in 82 patients. So we're not talking about 20 patients, we're talking about 82 patients over a long period of time. Overall response rate at 90%, MRD negative rate at 100%, not adding really any toxicity to the doublet on top of venetoclax. So our combination data is quite strong, and I think it really speaks to how we distinguish ourselves in the market when we're talking about other drugs.
6
rabbitsoup
$SNDX Earnings, abstracts and conference dates have been released. Unless I don't understand the window-Any and all insiders should be able to buy stock NOW in the open market with their own $. You would think-they would be jumping at this opportunity to buy cheap stock.. If they're allowed to buy, and don't think the stock is way oversold and worth purchasing at this price/valuation w upcoming milestones- they should not receive any shares (RSUs) rewards etc. A real leader/$KURA CEO recently purchased approx. $2MM of his stock in the open market at higher prices. If there are no$SNDX purchases -it shows-mngmt. is sleazy and not aligned at all with their shareholders. The $SNDX BOD have been treated with kid gloves and (no accountability) BOD need to respond directly to shareholders about the current stock price and multi-year-non-stop losses and how they dare justify handing out more free shares to executive losers while nobody is willing to purchase with their own $.
1
4
Burning_Cash
$SNDX Yesterday was likely a nothing burger for the share price IMHO. Both the numbers as well as the call. Still bullish, but it’ll take a while to see 20s again.
1
4
Tdorsey1776
$SNDX Repost...but isnt it more attractive now? Syndax (SNDX) earns the top takeover ranking with two FDA-approved drugs, 224% revenue growth, and co-partner Incyte named as the most logical acquirer.
6
Quantumup
Mizuho reit'd $SNDX Outperform-$43 and said--Tonight post the close, Syndax reported 3Q26 earnings and we caught up with management after the call. [KURA ABBV - RHHBY OTSKY BMY [INCY AVLN SNY]] Overall a good quarter: Revuforj in-line; actual $60.7MM vs consensus $60.8MM (Vara), and QoQ growth remained in double-digit territory at 11%. Notably, tonight management provided for the first time r/r NPM1m patient transplant and post-transplant maintenance therapy rates, ~40% and ~50%, respectively, surprisingly high for this patient population (recall, NPM1m patients tend to be older, less likely to be fit for transplant). This could be a tailwind for longer-term NPM1m patient sales, as duration on Revuforj as post-transplant maintenance could potentially be longer than for patients that stayed on therapy but didn't go to transplant. There may be a slight temporary headwind to NPM1m sales as patients go off therapy for transplant and recovery, but longer term we see this as moderately positive.
5
Georgeson
$SNDX From INCY Q3 results from this morning: In Q3, Niktimvo revenue rose to 67.368 million from $45.830 million = 47% increase. For 9 months to Sept 30, 2026, Niktimvo revenue rose to $182.765 million from $95.597 million = 91% increase. The expected third-quarter 2026 revenue (sales) for Niktimvo was pegged at $64 million, according to the Zacks Consensus Estimate. Niktimvo actually went on to beat these expectations, recording $67.4 million in net sales for the third quarter of 2026 (a 47% increase year-over-year). By aggregating the sequential quarterly consensus targets leading up to the Q3 2026 earnings release, the implied consensus expectation for Niktimvo's first 9 months of 2026 was approximately $179.4 million.
5
Hawksssss
$SNDX And so KMT2A patients are at about 60% getting maintenance. We expect that to go probably as high as 70%, 80% of patients getting maintenance, which would be a fantastic result. …..That should probably move up a little bit. 50% of them are getting maintenance. That could move to 60%, 70%, we believe. Well, it extends the duration of therapy for patients, and that leads to obviously enduring revenue, stacked revenue quarter over quarter. And we're seeing the evidence of that now. Last quarter, TRXs grew at 13%, next consecutive growth quarter for us. But certainly we would expect that to build into next year in 2027 as we start to see more and more patients come back for maintenance. And it's an exciting tailwind, if you will, for the relapsed/refractory business. I'll also say, as you get into frontline and you treat newly diagnosed patients, the ability to keep them on therapy for 12 months or more is where, you know, this extends to a $5 billion-plus business opportunity.
4
GrantDiaz
$SNDX Glad this is only a 5% position for me. This is brutal! I'm averaging down, but only slowly and cautiously.
4
rabbitsoup
$SNDX Kura Oncology's CEO purchased 200,000 shares for approximately $1.5 million. Once again here is what a real CEO is. Unlike SNDX CEO who keeps taking free shares as no long-term investor has made $ in his co.
4
roscoe44
$SNDX No bottom, biotech for past week has been relentless. Mlys mdgl kura sndx inbx nrix etc.. awful.
4
Georgeson
$SNDX transforms into a highly visible long-term "tailwind". • Bank of America (Jason Zemansky): Holds the lowest current estimate on Wall Street but maintained a Buy rating with a $23.00 price target (recently adjusted from $26.00 following an unrelated October pipeline miss in IPF trials). BofA is taking a more conservative approach toward the speed of market traction but remains focused on Syndax’s continued capture of the core market share. • Citi: Reaffirmed the highest price target on the street at $57.00. Citi analysts chose to focus on Niktimvo’s surging margin performance, which reached 34% in Q3. They noted that even adjusting for a minor one-time benefit, management’s upward revision of long-term margins to the low-to-mid 30% range (up from 25%-30%) signals a faster, clearer path toward company-wide profitability.
4
Tdorsey1776
$SNDX New CFO: Where the money flows.......Aaron has held senior finance positions at Vertex, Alexion, and Regeneron where he supported the company’s rapid expansion and a more than 20x growth multiple starting in 2010. Over his career, he has overseen more than $10 billion in strategic transactions, including the $5 billion acquisition of Mirati Therapeutics by Bristol Myers Squibb, where he served as CFO, and the $6.7 billion acquisition of Arena Pharmaceuticals by Pfizer. Aaron also served as CFO of Rocket Pharmaceuticals
4
Hawksssss
$SNDX . I mean, the ability to drive patients to transplant— realize that patients who had KMT2A refractory, relapsed refractory KMT2A or MPM1, disease were rarely transplanted. And now we're seeing rates upwards of 50%. So KMT2A, even when we started our— did our trial, our pivotal trial, about 25% of those patients were going to transplant. We're seeing 50% of them go to transplant now. And MPM1, 11%, 12% were getting transplanted. We're seeing 40% go to transplant. Also, on the other side, maintenance, not in the label, not something that we promote. This is all driven by physician choice. We're seeing 60% of the patients go to maintenance, meaning they go through their— they get a response.
3
rabbitsoup
$SNDX This trades like a pre-clininal or Phase 1 biotech with no revenue, short on cash.....
3
Kingjake26
$SNDX i remember when I sold this over twenty. Can’t believe it’s under $10. Bunch of  baloney. Ridiculous may start a new position here today.
3

Advertisement|Remove ads.